{
  "_metadata": {
    "version": "2.0",
    "ticker": "ARWR",
    "asset_name": "aro_alk7",
    "extracted_from": "ARWR Investment Thesis, Company Presentations",
    "extraction_date": "2026-02-05",
    "analyst_reviewed": true
  },
  "asset": {
    "name": "ARO-ALK7",
    "alternate_names": [],
    "company": "Arrowhead Pharmaceuticals",
    "ticker": "ARWR",
    "stage": "Phase 1/2",
    "modality": "RNAi (siRNA)",
    "ownership": "Wholly-owned",
    "one_liner": "Receptor-targeting approach to the activin E obesity pathway - orthogonal to ARO-INHBE"
  },
  "target": {
    "name": "ALK7",
    "full_name": "ACVR1C (Activin A Receptor Type 1C)",
    "class": "TGF-beta superfamily receptor",
    "pathway": "Activin E / ALK7 signaling in adipose tissue",
    "biology": {
      "simple_explanation": "ALK7 is the receptor for activin E in adipose tissue. While ARO-INHBE targets the ligand (activin E), ARO-ALK7 targets the receptor directly. Both approaches should block the same fat-storage pathway.",
      "pathway_detail": "ALK7 (ACVR1C) is expressed in adipocytes and binds activin E to promote lipid storage. Silencing ALK7 should block activin E signaling regardless of ligand levels.",
      "downstream_effects": [
        "Blocked activin E signaling at receptor level",
        "Potential weight loss similar to ARO-INHBE"
      ]
    },
    "why_good_target": {
      "rationale": "Orthogonal approach to same validated pathway as ARO-INHBE",
      "source": {
        "id": "arwr_thesis_2026",
        "verified": true
      }
    }
  },
  "mechanism": {
    "type": "RNAi (siRNA) via TRiM platform",
    "delivery": "Adipose tissue targeting (extra-hepatic)",
    "how_it_works": "ARO-ALK7 silences ALK7 (ACVR1C) mRNA in adipose tissue, preventing activin E from signaling through its receptor. This blocks fat accumulation and promotes weight loss through the same pathway as ARO-INHBE.",
    "differentiation_vs_inhbe": "Targets receptor (tissue-specific) vs ligand (liver-produced)",
    "source": {
      "id": "arwr_thesis_2026",
      "verified": true
    }
  },
  "indications": {
    "lead": {
      "name": "Obesity",
      "patient_population": "~100M US adults with obesity",
      "status": "Phase 1/2",
      "rationale": "Alternative approach if ARO-INHBE limited by ligand biology"
    },
    "expansion": [
      {
        "name": "Metabolic Dysfunction",
        "status": "Early evaluation"
      }
    ],
    "source": {
      "id": "arwr_thesis_2026",
      "verified": true
    }
  },
  "clinical_data": {
    "ongoing_trials": [
      {
        "trial_name": "ARO-ALK7 Phase 1/2",
        "nct_id": "NCT06937203",
        "phase": "Phase 1/2",
        "indication": "Obesity",
        "status": "Recruiting"
      }
    ]
  },
  "investment_analysis": {
    "bull_case": [
      {
        "point": "Orthogonal approach to same validated pathway",
        "evidence": "ALK7 is receptor for INHBE/activin E",
        "confidence": "Medium"
      },
      {
        "point": "Dual program gives optionality",
        "evidence": "ARWR can advance best candidate",
        "confidence": "High"
      },
      {
        "point": "Earlier stage means less dilution if successful",
        "evidence": "Phase 1/2 just started",
        "confidence": "Medium"
      }
    ],
    "bear_case": [
      {
        "point": "Even earlier stage than ARO-INHBE",
        "evidence": "No clinical data yet",
        "counter_argument": "Provides pipeline depth"
      },
      {
        "point": "Same GLP-1 competition",
        "evidence": "Wegovy/Zepbound dominating obesity market",
        "counter_argument": "Differentiated mechanism"
      },
      {
        "point": "May be redundant with ARO-INHBE",
        "evidence": "Same pathway targeted differently",
        "counter_argument": "Different tissue targeting may yield different profile"
      }
    ],
    "key_debates": [
      {
        "question": "Will ALK7 inhibition show differentiated profile vs ARO-INHBE?",
        "bull_view": "Receptor targeting in adipose may have different efficacy/safety",
        "bear_view": "Same pathway means similar results; one program sufficient",
        "what_resolves_it": "Head-to-head comparison of Phase 1/2 data"
      }
    ]
  },
  "competitive_landscape": [],
  "catalysts": [
    {
      "event": "Phase 1/2 initial data",
      "timing": "2026-2027",
      "importance": "Medium",
      "what_to_watch": "Weight loss, comparison to ARO-INHBE profile"
    }
  ],
  "sources": [
    {
      "id": "arwr_thesis_2026",
      "title": "ARWR Investment Thesis",
      "type": "Internal Analysis",
      "date": "2026-02-02"
    },
    {
      "id": "clinicaltrials",
      "title": "ClinicalTrials.gov",
      "type": "Clinical Trial Registry",
      "url": "https://clinicaltrials.gov/api/v2/studies"
    }
  ]
}
